EAM Investors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

EAM Investors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,779	Closed	-$1.7M	–	341
2020 Q1	$1.7M	Buy	11,779 +551	+5%	+$106K	0.53%	81
2019 Q4	$2.29M	Buy	11,228 +2,078	+23%	+$379K	0.5%	61
2019 Q3	$735K	Sell	9,150 -19,783	-68%	-$1.68M	0.19%	204
2019 Q2	$2.73M	Sell	28,933 -8,984	-24%	-$776K	0.67%	33
2019 Q1	$3.24M	Buy	37,917 +511	+1%	+$42.4K	0.8%	14
2018 Q4	$2.1M	Sell	37,406 -25,771	-41%	-$1.57M	0.57%	43
2018 Q3	$5.17M	Buy	+63,177	New	+$4.45M	0.77%	7

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's RETA Position: Q2 2020 in Review

EAM Investors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 11,779 shares — an estimated $1.7M sold.

EAM Investors first reported a position in RETA in Q3 2018 and held it in 7 quarters. The position peaked at $5.17M in Q3 2018. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

EAM Investors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
EAM Investors sold 11,779 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $1.7M.
EAM Investors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 7 quarters.
EAM Investors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.17M in Q3 2018.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.